Longeveron (LGVN) FCF Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) FCF Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Margin Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
5,389.00 |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
1,525.00 |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Longeveron |
20.35 Bn |
20.33 Bn |
264,000.00 |
14,191.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
14,191.00 |
| Dec 31, 2025 |
-88,943.00 |
| Sep 30, 2025 |
-330,797.00 |
| Jun 30, 2025 |
-17,172.00 |
| Mar 31, 2025 |
-67,384.00 |
| Dec 31, 2024 |
604,324.00 |
| Sep 30, 2024 |
261,592.00 |
| Jun 30, 2024 |
114,515.00 |
| Mar 31, 2024 |
154,505.00 |
| Dec 31, 2023 |
-464,278.00 |
| Sep 30, 2023 |
157,267.00 |
| Jun 30, 2023 |
-144,314.00 |
| Mar 31, 2023 |
-97,625.00 |
| Dec 31, 2022 |
-119,978.00 |
| Sep 30, 2022 |
-359,002.00 |
| Jun 30, 2022 |
-11,585.00 |
| Mar 31, 2022 |
-32,848.00 |
| Dec 31, 2021 |
-75,297.00 |
| Sep 30, 2021 |
-100,879.00 |
| Jun 30, 2021 |
-19,401.00 |
